Drug Interactions between concizumab and emicizumab
This report displays the potential drug interactions for the following 2 drugs:
- concizumab
- emicizumab
Interactions between your drugs
emicizumab concizumab
Applies to: emicizumab and concizumab
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Concomitant or consecutive use of concizumab and emicizumab may have additive effects on thrombin generation and increase the risk of thrombosis. In clinical studies, hemophilia A patients with FVIII inhibitors were required to discontinue emicizumab for at least 180 days before receiving concizumab. Clinical data about this interaction are lacking.
MANAGEMENT: When changing from another anti-tissue factor pathway inhibitor product to concizumab, the previous product's half-life should be taken into consideration. Due to the long half-life of emicizumab, some authorities recommend that it be ceased for at least 180 days prior to starting treatment with concizumab in Hemophilia A patients with FVIII inhibitors. Close monitoring for thromboembolic events is recommended in patients with known risk factors for thromboembolism (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking). Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.